KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer
出版年份 2015 全文链接
标题
KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer
作者
关键词
-
出版物
Future Oncology
Volume 11, Issue 13, Pages 1919-1929
出版商
Future Medicine Ltd
发表日期
2015-07-10
DOI
10.2217/fon.15.97
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study
- (2013) B. Schultheis et al. ANNALS OF ONCOLOGY
- Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
- (2013) Roberta Schmieder et al. INTERNATIONAL JOURNAL OF CANCER
- KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer
- (2013) D. P. Modest et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
- (2012) D Strumberg et al. BRITISH JOURNAL OF CANCER
- A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
- (2012) K. Mross et al. CLINICAL CANCER RESEARCH
- KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines
- (2012) Isabelle Messner et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Activation of the RAS/RAF/ERK Signaling Pathway Contributes to Resistance to Sunitinib in Thyroid Carcinoma Cell Lines
- (2012) Annamaria Piscazzi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Association ofKRASG13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
- (2012) Sabine Tejpar et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status
- (2011) Dominik P. Modest et al. ANTI-CANCER DRUGS
- The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104-trial
- (2011) D.P. Modest et al. INTERNATIONAL JOURNAL OF CANCER
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- AAV-mediated gene targeting methods for human cells
- (2011) Iram F Khan et al. Nature Protocols
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer
- (2009) Jens Neumann et al. PATHOLOGY RESEARCH AND PRACTICE
- Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses
- (2008) F. Di Nicolantonio et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search